Navigation Links
Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
Date:12/14/2008

SAN ANTONIO, Dec. 14 /PRNewswire/ -- Results from a Phase 3 study show that patients with metastatic breast cancer who were treated previously with an anthracycline in the adjuvant setting experienced a significant improvement in time to disease progression (TTP) and overall response rates after receiving a combination of DOXIL(R) (doxorubicin HCl liposome injection) and docetaxel as compared to docetaxel alone.

Results from this randomized, parallel-group, open-label, multi-center study were presented today at the 31st Annual San Antonio Breast Cancer Symposium (SABCS). The study included only patients previously treated with anthracyclines who had a disease-free interval of at least one year.

The study found that patients treated with the DOXIL and docetaxel combination had a 35% risk reduction for developing disease progression compared with docetaxel alone (hazard ratio = 0.65; 95% confidence interval [0.55, 0.77]; p=0.000001). There is an almost three-month improvement in median TTP for patients treated with the combination compared with docetaxel monotherapy (9.8 versus 7.0 months, respectively).

The safety profile was consistent with known toxicities of the two agents. Additionally, the incidence of symptomatic cardiac events was 5% in the combination group versus 4% in the monotherapy group (>/= Grade 2 cardiac adverse events). Symptomatic congestive heart failure was reported in 1% of subjects in both groups. Arrhythmia was reported in 4% of the combination group and 3% of the monotherapy group. Protocol-defined LVEF decreases occurred in 5% of subjects in both groups.

"Anthracyclines are active drugs for metastatic breast cancer, but concerns about cardiac toxicity have prevented oncologists from using them in those who received anthracyclines as part of their adjuvant therapy," said Dr. Joseph Sparano, Director of the Breast Evaluation Center at the Montefiore-Einstein Cancer Center and Professor of Medicine & Women's Health at the Albert Einstein College of Medicine in New York, and lead investigator on the study. "The study suggests that the combination of DOXIL and docetaxel may be an effective treatment for patients with metastatic breast cancer who have relapsed after prior adjuvant anthracycline therapy."

Study Background

The study enrolled 751 women in 19 countries. Patients were randomly assigned to one of two treatment arms: DOXIL 30 mg/m2 followed by docetaxel 60 mg/m2 on the first day of every 21-day cycle; or docetaxel 75 mg/m2 on the first day of every 21-day cycle. Treatment continued until an unacceptable treatment-related toxicity or disease progression occurred.

The primary endpoint of the study was time to progression, as determined by independent reviewers blinded to study treatment. Secondary endpoints included response rate, overall survival and safety.

Response rates (the percentage of patients whose cancer shrinks after treatment) in patients treated with the DOXIL and docetaxel combination were significantly higher than those treated with docetaxel monotherapy (35% versus 26% respectively; p= 0.0085). Overall survival data were not yet mature; a final protocol-specified survival analysis is planned after the occurrence of 485 events.

The most common adverse reactions (e.g., those occurring in at least 20% of the patients) for the DOXIL and docetaxel combination compared to the monotherapy group, respectively, were:

     * Hematological toxicities and infections, including:
         - Neutropenia - 66% (Grade 3/4 57%) versus 65% (Grade 3/4 59%), with
           febrile neutropenia reported in 7% versus 6% of patients
         - Anemia - 20% (Grade 3/4 2%) versus 17% (Grade 3/4 1%)
         - Infection - 30% (Grade 3/4 5%) versus 25% (Grade 3/4 2%)
     * Hand-foot syndrome:  61% (Grade 3/4 24%) versus 1% (Grade 3/4 0%)
     * Stomatitis:  52% (Grade 3/4 11%) versus 14% (Grade 3/4 1%)
     * Alopecia:  48% versus 45%
     * Asthenia:  29% (Grade 3/4 4%) versus 20% (Grade 3/4 3%)
     * Nausea:  28% (Grade 3/4 1%) versus 22% (Grade 3/4 <1%)
     * Fatigue: 20% (Grade 3/4 3%) versus 15% (Grade 3/4 2%)

The study was sponsored by Ortho Biotech Oncology Research & Development (ORD), a unit of Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

About DOXIL(R)

DOXIL is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after prior platinum based therapy. DOXIL in combination with VELCADE(R) (bortezomib) is indicated for the treatment of patients with multiple myeloma who have not previously received VELCADE and have received at least one prior therapy. DOXIL is also indicated for the treatment of AIDS-related Kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy.

    IMPORTANT SAFETY INFORMATION

BOXED WARNINGS:

Cardiotoxicity, infusion reaction, myelosuppression, liver impairment, substitution

     * The use of DOXIL may lead to cardiac toxicity. Myocardial damage may
       lead to congestive heart failure and may occur as the total cumulative
       dose of doxorubicin HCl approaches 550 mg/m2
         - Prior use of other anthracyclines or anthracenediones should be
           included in calculations of total cumulative dose
         - Cardiac toxicity may also occur at lower cumulative doses (400
           mg/m2) in patients with prior mediastinal irradiation or who are
           receiving concurrent cyclophosphamide therapy
     * Acute infusion-related reactions including, but not limited to,
       flushing, shortness of breath, facial swelling, headache, chills, back
       pain, tightness in the chest or throat, and/or hypotension have
       occurred in up to 10% of patients treated with DOXIL. In most patients,
       these reactions have resolved within several hours to a day once the
       infusion is terminated. In some patients, reactions resolved with
       slowing of the infusion rate
         - Serious and sometimes life-threatening or fatal
           allergic/anaphylactoid-like infusion reactions have occurred.
           Medications to treat such reactions, as well as emergency
           equipment, should be available for immediate use
         - The initial rate of infusion should be 1 mg/min to minimize the
           risk of infusion reactions
     * Severe myelosuppression may occur
     * DOXIL dosage should be reduced in patients with impaired hepatic
       function
     * Accidental substitution has resulted in severe side effects. Do not
       substitute for doxorubicin HCl on a mg per mg basis


    Contraindications
     * Patients with a history of hypersensitivity reactions to a conventional
       doxorubicin formulation or the components of DOXIL
     * Nursing mothers


    Additional Safety Information
     * Cardiac function should be carefully monitored
         - Congestive heart failure or cardiomyopathy may occur after
           discontinuation of anthracycline therapy
         - For patients with a history of cardiovascular disease, or if the
           results of cardiac monitoring indicate possible cardiac injury, the
           benefit of therapy must be weighed against the risk of myocardial
           injury
         - In the randomized multiple myeloma study, 25 patients (8%) in the
           VELCADE for Injection arm and 42 patients (13%) in the VELCADE plus
           DOXIL arm experienced left ventricular ejection fraction decrease
           (defined as absolute decrease >/= 15% over baseline or a >/= 5%
           decrease below institutional lower limit of normal)
     * Myelosuppression may occur; frequently monitor complete blood count
       (including platelet count), at least prior to each dose of DOXIL
         - In patients with recurrent ovarian cancer or AIDS-related Kaposi's
           sarcoma, hematologic toxicity (based on platelet count or absolute
           neutrophil count) may require dose reduction or delay in
           administration of DOXIL
         - In patients with multiple myeloma, hematologic toxicity (based on
           platelet count, absolute neutrophil count, hemoglobin level, or
           neutropenia with fever) may require dose reduction, delay in
           administration, or suspension of DOXIL and/or VELCADE
         - Persistent severe myelosuppression may result in superinfection,
           neutropenic fever, or hemorrhage
         - Sepsis occurring during neutropenia has resulted in discontinuation
           of treatment and in rare cases of death
     * DOXIL may potentiate the toxicity of other anticancer therapies,
       especially hematologic toxicities, when used in combination with other
       therapies that suppress bone marrow
     * Hand-foot syndrome (HFS) may occur during therapy with DOXIL
         - Based on HFS toxicity grade, dose reduction, or delay in
           administration, or discontinuation of DOXIL may be required
         - HFS was generally observed after 2 to 3 cycles of treatment, but
           may occur earlier
         - The reaction was mild in most patients, resolving in 1 to 2 weeks
         - The reaction can be severe and debilitating in some patients,
           resulting in discontinuation of therapy
     * DOXIL is an irritant, not a vesicant; use precautions to avoid
       extravasation
     * DOXIL can cause fetal harm when used during pregnancy
     * Recall reaction has occurred with DOXIL administration after
       radiotherapy
     * DOXIL may interact with drugs known to interact with the conventional
       formulation of doxorubicin HCl
     * In patients with recurrent ovarian cancer, the most common all-grade
       adverse reactions (ARs) >20% (DOXIL vs topotecan, respectively)
       included: asthenia (40% vs 51%), fever (21% vs 31%), nausea (46% vs
       63%), stomatitis (41% vs 15%), vomiting (33% vs 44%), diarrhea (21% vs
       35%), anorexia (20% vs 22%), dyspnea (15% vs 23%), HFS (51% vs 1%), and
       rash (29% vs 12%)
         - In addition, 19% vs 52.3% reported alopecia (all grades)
         - Grade 3/4 hematologic ARs reported in >5% (DOXIL vs topotecan,
           respectively) were neutropenia (12% vs 76%) and anemia (6% vs 29%)
     * In patients with multiple myeloma, the most common all-grade ARs >20%
       (VELCADE plus DOXIL vs VELCADE, respectively) included: neutropenia
       (36% vs 22%), thrombocytopenia (33% vs 28%), anemia (25% vs 21%),
       fatigue (36% vs 28%), pyrexia (31% vs 22%), asthenia (22% vs 18%),
       nausea (48% vs 40%), diarrhea (46% vs 39%), vomiting (32% vs 22%),
       constipation (31% vs 31%), mucositis/stomatitis (20% vs 5%), peripheral
       neuropathy (42% vs 45%), neuralgia (17% vs 20%), and rash (22% vs 18%)
         - In addition, 19% vs <1% reported HFS
     * In patients with AIDS related Kaposi's sarcoma, ARs reported in >/= 5%
       of DOXIL-treated patients were: neutropenia (ANC <1000/mm3, 46%;
       <500/mm3, 11%), anemia (Hb <10 g/dL, 58%; <8 g/dL, 16%),
       thrombocytopenia (<150,000 platelets/mm3, 61%), nausea (18%), asthenia
       (7%), fever (8%), alopecia (9%), vomiting (8%), diarrhea (5%), and
       stomatitis (5%)

Please see accompanying full Prescribing Information, including Boxed WARNINGS.

About Ortho Biotech Products, L.P.

Ortho Biotech Products, L.P. is a leading biopharmaceutical company devoted to helping improve the lives of patients with cancer and with anemia due to multiple causes, including chronic kidney disease. Since it was founded in 1990, Ortho Biotech and its worldwide affiliates have earned a global reputation for researching, manufacturing and marketing innovative products that enhance patients' health. Located in Bridgewater, N.J., Ortho Biotech is an established market leader in anemia management. The company also markets treatments for recurrent ovarian cancer, rejection of transplanted organs and other serious illnesses. For more information, visit www.orthobiotech.com.

Ortho Biotech Products, L.P. is a member of the Johnson & Johnson Family of Companies.

Forward-Looking Statement

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.


'/>"/>
SOURCE Ortho Biotech Products, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Major deCODE-led Study Underscores Role of the Brain in Obesity
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
4. Genomas Clinical Study Finds Increased Prevalence of Drug Metabolism Deficiencies in Patients With Serious Psychotropic Side Effects
5. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
6. New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
7. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
8. Neuronetrix Announces Preliminary Alzheimers Study Results at the Society for Neuroscience Conference
9. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
10. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
11. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)...   GS1 US will hold a series ... GS1 Standards implementation to address the requirements of the ... (UDI) rule. Scott Brown , director ... senior director industry development, medical devices, GS1 US; and ... --> Scott Brown , director ...
(Date:2/8/2016)... NORRITON, Pa. , Feb. 8, 2016 /PRNewswire/ ... of November Research Group (NRG),s pharmacovigilance technology ... pharmacovigilance system-related consulting services and an Oracle Argus ... compliance services to Life Sciences companies. ... strengthens and expands HighPoint,s life sciences capabilities and ...
(Date:2/8/2016)... PALO ALTO, Calif. , Feb. 8, 2016 ... chemical manufacturing, and Kodiak Sciences Inc., a biopharmaceutical company ... retinal disease, announced today agreements for the clinical supply ... manufacture material at multiple sites, including Slough (UK), Visp ... --> Retinal diseases, such as age-related ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published ... rate of type 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin ... a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Guruji Mahendra ... 9th, 10th and 11th, 2016 in honor of his birthday on February 10th. ... happiness. Mahendra Trivedi is known by over 250,000 people from over 40 different ...
(Date:2/7/2016)... ... February 07, 2016 , ... Women's Excellence staff, in all four locations, wore ... Wear Red Day is the first Friday each February and a day to bring ... in 3 deaths among women each year – more than all cancers combined. Go ...
(Date:2/6/2016)... San Rafael, CA (PRWEB) , ... February 06, 2016 , ... ... 2016 Youth Ultimate Coaching Conference (YUCC) . This event brings together top non-profit leaders, ... is “Gender Equity and Girls Ultimate”. Valerio Iani, Bay Area Disc Program Director of ...
(Date:2/5/2016)... ... February 05, 2016 , ... Steven Tonkinson, 36, of Coconut Grove, Florida, ran ... it started in 2003. This year, he ran all 26.2 miles with a green ... team the Miami Heat. , This Sunday, while many are watching the Superbowl, Steven ...
Breaking Medicine News(10 mins):